Protacs in Cancer Therapy: Mechanisms, Design, Clinical Trials, and Future Directions

Overview

Journal Drug Deliv Transl Res

Publisher Springer

Specialty Pharmacology

Date 2024 Nov 29

PMID 39614036

Authors

Akash Vikal

Rashmi Maurya

Brij Bihari Patel

Rajeev Sharma

Preeti Patel

Umesh K Patil

Balak Das Kurmi

Affiliations

Soon will be listed here.

Abstract

Cancer develops as a result of changes in both genetic and epigenetic mechanisms, which lead to the activation of oncogenes and the suppression of tumor suppressor genes. Despite advancements in cancer treatments, the primary approach still involves a combination of chemotherapy, radiotherapy, and surgery, typically providing a median survival of approximately five years for patients. Unfortunately, these therapeutic interventions often bring about substantial side effects and toxicities, significantly impacting the overall quality of life for individuals undergoing treatment. Therefore, urgent need of research required which comes up with effective treatment of cancer. This review explores the transformative role of Proteolysis-Targeting Chimeras (PROTACs) in cancer therapy. PROTACs, an innovative drug development strategy, utilize the cell's protein degradation machinery to selectively eliminate disease-causing proteins. The review covers the historical background, mechanism of action, design, and structure of PROTACs, emphasizing their precision in targeting oncogenic proteins. The discussion extends to the challenges, nanotechnology applications, and ongoing clinical trials, showcasing promising results and clinical progress. The review concludes with insights into patents, future directions, and the potential impact of PROTACs in addressing dysregulated protein expression across various diseases. Overall, it provides a concise yet comprehensive overview for researchers, clinicians, and industry professionals involved in developing targeted therapies.

References

Disis M, Cheever M . Oncogenic proteins as tumor antigens. Curr Opin Immunol. 1996; 8(5):637-42. DOI: 10.1016/s0952-7915(96)80079-3. View

Blume-Jensen P, Hunter T . Oncogenic kinase signalling. Nature. 2001; 411(6835):355-65. DOI: 10.1038/35077225. View

Goodell V, Salazar L, Urban N, Drescher C, Gray H, Swensen R . Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol. 2006; 24(5):762-8. DOI: 10.1200/JCO.2005.03.2813. View

Maddalo D, Manchado E, Concepcion C, Bonetti C, Vidigal J, Han Y . In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system. Nature. 2014; 516(7531):423-7. PMC: 4270925. DOI: 10.1038/nature13902. View

Lepourcelet M, Chen Y, France D, Wang H, Crews P, Petersen F . Small-molecule antagonists of the oncogenic Tcf/beta-catenin protein complex. Cancer Cell. 2004; 5(1):91-102. DOI: 10.1016/s1535-6108(03)00334-9. View

Zhang B . CRISPR/Cas gene therapy. J Cell Physiol. 2020; 236(4):2459-2481. DOI: 10.1002/jcp.30064. View

Zhang Z, Zhang Y, Gao F, Han S, Cheah K, Tse H . CRISPR/Cas9 Genome-Editing System in Human Stem Cells: Current Status and Future Prospects. Mol Ther Nucleic Acids. 2017; 9:230-241. PMC: 5651489. DOI: 10.1016/j.omtn.2017.09.009. View

Pettersson M, Crews C . PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future. Drug Discov Today Technol. 2019; 31:15-27. PMC: 6578591. DOI: 10.1016/j.ddtec.2019.01.002. View

10.

Li R, Liu M, Yang Z, Li J, Gao Y, Tan R . Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future. Molecules. 2022; 27(24). PMC: 9785308. DOI: 10.3390/molecules27248828. View

11.

Yang Q, Zhao J, Chen D, Wang Y . E3 ubiquitin ligases: styles, structures and functions. Mol Biomed. 2022; 2(1):23. PMC: 8607428. DOI: 10.1186/s43556-021-00043-2. View

12.

Danishuddin , Jamal M, Song K, Lee K, Kim J, Park Y . Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development. Pharmaceuticals (Basel). 2023; 16(12). PMC: 10747325. DOI: 10.3390/ph16121649. View

13.

Nalawansha D, Crews C . PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020; 27(8):998-1014. PMC: 9424844. DOI: 10.1016/j.chembiol.2020.07.020. View

14.

McCoull W, Cheung T, Anderson E, Barton P, Burgess J, Byth K . Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC To Provide Insight into Small Molecule Targeting of BCL6. ACS Chem Biol. 2018; 13(11):3131-3141. DOI: 10.1021/acschembio.8b00698. View

15.

Bassi Z, Fillmore M, Miah A, Chapman T, Maller C, Roberts E . Modulating PCAF/GCN5 Immune Cell Function through a PROTAC Approach. ACS Chem Biol. 2018; 13(10):2862-2867. DOI: 10.1021/acschembio.8b00705. View

16.

Zorba A, Nguyen C, Xu Y, Starr J, Borzilleri K, Smith J . Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc Natl Acad Sci U S A. 2018; 115(31):E7285-E7292. PMC: 6077745. DOI: 10.1073/pnas.1803662115. View

17.

Popow J, Arnhof H, Bader G, Berger H, Ciulli A, Covini D . Highly Selective PTK2 Proteolysis Targeting Chimeras to Probe Focal Adhesion Kinase Scaffolding Functions. J Med Chem. 2019; 62(5):2508-2520. DOI: 10.1021/acs.jmedchem.8b01826. View

18.

Nunes J, McGonagle G, Eden J, Kiritharan G, Touzet M, Lewell X . Targeting IRAK4 for Degradation with PROTACs. ACS Med Chem Lett. 2019; 10(7):1081-1085. PMC: 6627720. DOI: 10.1021/acsmedchemlett.9b00219. View

19.

Xiao M, Zhao J, Wang Q, Liu J, Ma L . Recent Advances of Degradation Technologies Based on PROTAC Mechanism. Biomolecules. 2022; 12(9). PMC: 9496103. DOI: 10.3390/biom12091257. View

20.

Liu Z, Hu M, Yang Y, Du C, Zhou H, Liu C . An overview of PROTACs: a promising drug discovery paradigm. Mol Biomed. 2022; 3(1):46. PMC: 9763089. DOI: 10.1186/s43556-022-00112-0. View

21.

Li K, Crews C . PROTACs: past, present and future. Chem Soc Rev. 2022; 51(12):5214-5236. PMC: 10237031. DOI: 10.1039/d2cs00193d. View